SGLT2 inhibitors, such as empagliflozin and dapagliflozin, have demonstrated positive effects in NAFLD patients by reducing liver fat content and improving liver function tests in predominantly diabetic patients. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.